INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01801 INNOVENT BIO

Not Yet Opened 10-27 16:08:21

80.700

-2.000

-2.42%

High84.400	Low80.000	Vol11.39M
Open84.400	D1 Closing82.700	Amplitude5.32%
Mkt Cap140.98B	Tradable Cap140.98B	Total Shares1.75B
T/O922.85M	T/O Rate0.65%	Tradable Shares1.75B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"INNOVENT BIO","latestPrice":80.7,"timestamp":1793088501005,"preClose":82.7,"halted":0,"volume":11386954,"delay":0,"changeRate":-0.02418379685610641,"floatShares":1747000000,"shares":1747000000,"eps":0.469999,"marketStatus":"Not Yet Opened","change":-2,"latestTime":"10-27 16:08:21","open":84.4,"high":84.4,"low":80,"amount":922851113,"amplitude":0.053204,"askPrice":80.75,"askSize":35500,"bidPrice":80.7,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":0.803379,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1793151000000},"marketStatusCode":0,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":82.7,"openAndCloseTimeList":[[1793064600000,1793073600000],[1793077200000,1793088000000]],"volumeRatio":0.7251280088253893,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.5658,"impliedVolPercentile":0.8571},"requestUrl":"/m/hq/s/01801/tweets","defaultTab":"tweets","newsList":[{"id":"1194803525","title":"Movement Alert｜INNOVENT BIO Falls 3.02% in Regular Trading, Biotech Sector Pullback Overshadows Recent ESMO Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=1194803525","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194803525?lang=en_us&edition=fundamental","pubTime":"2026-10-27 14:12","pubTimestamp":1793081535,"startTime":"0","endTime":"0","summary":"On October 27, INNOVENT BIO fell 3.02% in regular trading, trading at HK$80.2, with turnover of HK$488 million.The most direct backdrop in publicly available information is a broad biotechnology...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Schroders Stake Raise Fails to Halt INNOVENT BIO Decline","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678165035","title":"China Accepts Innovent's Sintilimab Combination for Melanoma Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2678165035","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678165035?lang=en_us&edition=fundamental","pubTime":"2026-10-26 17:19","pubTimestamp":1793006364,"startTime":"0","endTime":"0","summary":"China Accepts Innovent's Sintilimab Combination for Melanoma ReviewChina’s NMPA accepted Innovent Biologics’ application for sintilimab with Nolgileucel (GC101) for advanced melanoma.The proposed indi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nNDL9cyx8c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1188198961.HKD","01801","KURE","HK0000165453.HKD","BK1589","LU0149534421.HKD","LU2097828631.EUR","LU0244354667.USD","LU2097828474.EUR","LU0463099449.HKD","LU0455707207.USD","LU2097828805.USD","BK1161","LU1831875114.USD","LU2097828714.EUR","LU0607220059.USD","LU0326950275.SGD","LU0502904849.HKD","LU2097828557.USD","LU2242644610.SGD","BK1147","LU1969619763.USD","LU2328871848.SGD","01911","LU2488822045.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678165779","title":"Innovent Announces Nmpa Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2678165779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678165779?lang=en_us&edition=fundamental","pubTime":"2026-10-26 17:18","pubTimestamp":1793006280,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nTUA420RJ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2097828474.EUR","BK1583","LU2097828805.USD","LU1188198961.HKD","HK0000165453.HKD","KURE","BK1589","LU2097828714.EUR","LU0463099449.HKD","LU1969619763.USD","LU2097828557.USD","LU0326950275.SGD","LU2328871848.SGD","LU0244354667.USD","LU2488822045.USD","BK1161","01801","LU0149534421.HKD","LU2097828631.EUR","LU2242644610.SGD","LU1831875114.USD","LU0502904849.HKD","LU0607220059.USD","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678168609","title":"Innovent Biologics Presents Phase 3 Data Showing Arcotatug Tavetecan Meets Survival Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2678168609","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678168609?lang=en_us&edition=fundamental","pubTime":"2026-10-26 16:21","pubTimestamp":1793002902,"startTime":"0","endTime":"0","summary":"Innovent Biologics Presents Phase 3 Data Showing Arcotatug Tavetecan Meets Survival EndpointsInnovent Biologics’ arcotatug tavetecan met overall survival and progression-free survival endpoints in the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nNDL5rM98Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","LU0455707207.USD","LU0149534421.HKD","LU0244354667.USD","LU0607220059.USD","LU2097828805.USD","LU1831875114.USD","LU2097828474.EUR","LU0463099449.HKD","LU1188198961.HKD","LU2097828714.EUR","01911","HK0000165453.HKD","BK1583","01801","BK1161","LU2488822045.USD","BK1147","BK1589","LU0326950275.SGD","LU1969619763.USD","LU2242644610.SGD","LU0502904849.HKD","LU2097828557.USD","LU2097828631.EUR","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678340331","title":"Innovent's Ibi363 Plus Bevacizumab Cuts Progression or Death Risk 60% in Phase 1b Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2678340331","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678340331?lang=en_us&edition=fundamental","pubTime":"2026-10-26 08:00","pubTimestamp":1792972840,"startTime":"0","endTime":"0","summary":"Innovent's IBI363 Plus Bevacizumab Cuts Progression or Death Risk 60% in Phase 1b Lung Cancer TrialInnovent Biologics announced Oct. 25, 2026, that Phase 1b results for IBI363/TAK-928, jointly develop","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nNDL3PxMBR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0149534421.HKD","LU1969619763.USD","BK1161","LU2328871848.SGD","LU0326950275.SGD","LU2242644610.SGD","LU1188198961.HKD","BK1589","LU2097828805.USD","LU2097828557.USD","LU0463099449.HKD","LU1831875114.USD","01911","BK1147","LU2097828631.EUR","LU0607220059.USD","LU0455707207.USD","KURE","LU0244354667.USD","HK0000165453.HKD","BK1583","LU2488822045.USD","LU2097828714.EUR","01801","LU2097828474.EUR","LU0502904849.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678136123","title":"Takeda to Seek Japan Approval for Gastric Cancer Drug Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2678136123","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678136123?lang=en_us&edition=fundamental","pubTime":"2026-10-26 02:59","pubTimestamp":1792954779,"startTime":"0","endTime":"0","summary":"Takeda to seek Japan approval for gastric cancer drug next yearMADRID, Oct 25 (Reuters)-Takeda Pharmaceutical4502.Tplans to seek regulatory approval in Japan next year for its gastric cancer drug, aft","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261025:nL3N46B02E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0887340254.USD","LU1481599808.USD","LU0052756011.USD","LU1015430645.USD","LU2242644610.SGD","LU2114397693.USD","LU0047473722.EUR","LU0171293334.USD","LU1153584641.USD","LU1923622614.USD","LU1863844665.USD","LU0784385840.USD","LU1170363599.USD","IE00BJT1NW94.SGD","LU2433249047.HKD","LU2125909593.SGD","LU1051770623.HKD","LU1084165304.USD","LU0211331839.USD","LU2091194634.USD","LU2089284900.SGD","LU2125909247.SGD","LU0326950275.SGD","LU1989771016.USD","LU2357627491.SGD","LU2108987350.USD","LU1814569148.SGD","LU0345777147.USD","LU1989772840.SGD","LU0857590862.USD","AZN.UK","LU1301847155.USD","03165","LU1267930573.SGD","BK1583","LU0963555726.SGD","LU0499090636.EUR","KURE","01801","LU0949170426.SGD","LU0158827948.USD","LU1078025761.USD","LU2097828714.EUR","LU0964806797.USD","SG9999001176.USD","LU1064927863.SGD","LU1487256676.USD","LU0266013472.USD","LU0957799991.USD","LU0976567544.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678135324","title":"AstraZeneca's Stomach Cancer Drug Clears Bar for Extending Overall Survival in Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2678135324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678135324?lang=en_us&edition=fundamental","pubTime":"2026-10-25 23:30","pubTimestamp":1792942201,"startTime":"0","endTime":"0","summary":"AstraZeneca's stomach cancer drug clears bar for extending overall survival in late-stage studyMADRID, Oct 25 (Reuters)-AstraZeneca'sAZN.Lexperimental drug sone-ve helped patients with advanced stomac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261025:nL4N4691TE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211327993.USD","LU2089284900.SGD","LU0823416689.USD","IE00BJJMRZ35.SGD","LU1496350171.SGD","LU0964806797.USD","03165","LU2097828474.EUR","LU2114397693.USD","LU0244354667.USD","LU1023059063.AUD","LU0432979614.USD","LU1051770623.HKD","LU1003077747.HKD","LU1046234339.USD","LU1153585028.USD","LU0011850046.USD","LU2357627491.SGD","KURE","IE00B4R5TH58.HKD","LU0203347892.USD","LU0859254822.USD","LU1188198961.HKD","LU0949170772.SGD","LU1015430645.USD","LU1496350502.SGD","LU0661504455.SGD","LU2097828631.EUR","LU0857590862.USD","LU2539964713.USD","LU0128525689.USD","LU0553294199.USD","LU0889566641.SGD","SMMT","LU0266013472.USD","LU1989771016.USD","LU0149534421.HKD","LU1196032939.SGD","LU0128525929.USD","LU0784385840.USD","LU0640478417.SGD","SG9999013999.USD","LU2468319806.SGD","01801","IE00BJT1NW94.SGD","AZN.UK","IE0002141913.USD","LU0326950275.SGD","LU1323610961.USD","LU0211326839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678136256","title":"Could Phase 3 Cancer Trial Success Alter The Investment Case For Innovent Biologics (SEHK:1801)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2678136256","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678136256?lang=en_us&edition=fundamental","pubTime":"2026-10-25 22:26","pubTimestamp":1792938385,"startTime":"0","endTime":"0","summary":"Innovent Biologics reported positive Phase 3 G-HOPE-001 data for arcotatug tavatecan in previously treated CLDN18.2-positive advanced gastric and gastroesophageal junction cancer, showing statistically significant gains in survival and response rates versus physician’s choice therapies, with a manageable safety profile and an active priority regulatory review in China.\nThe arcotatug tavatecan program positions Innovent Biologics as an early mover in CLDN18.2-directed antibody drug...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/could-phase-3-cancer-trial-success-alter-the-investment-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/could-phase-3-cancer-trial-success-alter-the-investment-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0149534421.HKD","LU2328871848.SGD","LU2097828805.USD","LU2097828557.USD","LU0455707207.USD","LU2242644610.SGD","LU2097828714.EUR","LU0244354667.USD","HK0000165453.HKD","LU0502904849.HKD","BK1583","LU2488822045.USD","LU2097828631.EUR","LU0326950275.SGD","LU0463099449.HKD","KURE","LU2097828474.EUR","LU0607220059.USD","LU1831875114.USD","BK1161","LU1188198961.HKD","LU1969619763.USD","01801","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150822607","title":"New Growth Drivers Take Center Stage as China's Economy Accelerates","url":"https://stock-news.laohu8.com/highlight/detail?id=1150822607","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150822607?lang=en_us&edition=fundamental","pubTime":"2026-10-25 18:01","pubTimestamp":1792922468,"startTime":"0","endTime":"0","summary":"Since the beginning of this year, China's new growth drivers have been rapidly expanding, playing an increasingly strong role in fueling the economy.Data from the National Development and Reform...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU0405327148.USD","LU0502904849.HKD","BK0028","LU1064130708.USD","LU1255011170.USD","BK0188","LU1328615791.USD","BK0183","LU0405327494.USD","01801","LU2148510915.USD","LU0149534421.HKD","BK1589","LU1997245094.SGD","BK0196","LU2580892862.HKD","BK0060","LU1655091616.SGD","LU2097828805.USD","600276","BK1583","LU1831875114.USD","BK0239","LU1064131003.USD","LU1146622755.USD","LU2097828474.EUR","01276","LU1997244956.HKD","LU2495084118.USD","LU2328871848.SGD","BK1161","HK0000165453.HKD","BK0012","LU2097828631.EUR","LU2488822045.USD","LU1580142542.USD","LU0455707207.USD","LU0463099449.HKD","LU2097828557.USD","LU0607220059.USD","LU2242644610.SGD","KURE","LU1188198961.HKD","LU1820825898.SGD","LU2289578879.USD","LU2580892789.USD","LU0326950275.SGD","LU1997245177.USD","LU2097828714.EUR","LU0244354667.USD","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678184170","title":"Innovent's Ibi354-Pertuzumab Combination Shows 95% Response Rate in Phase 2 Breast Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2678184170","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678184170?lang=en_us&edition=fundamental","pubTime":"2026-10-25 14:00","pubTimestamp":1792908044,"startTime":"0","endTime":"0","summary":"Innovent's IBI354-Pertuzumab Combination Shows 95% Response Rate in Phase 2 Breast Cancer TrialInnovent Biologics presented Phase 2 results for IBI354 with pertuzumab in first-line HER2-positive advan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261025:nNDL9lY53W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","BK1583","LU2097828805.USD","LU1188198961.HKD","HK0000165453.HKD","KURE","BK1589","LU2097828714.EUR","LU0463099449.HKD","LU1969619763.USD","LU2097828557.USD","LU0326950275.SGD","LU2328871848.SGD","LU0244354667.USD","LU2488822045.USD","BK1161","01801","LU0149534421.HKD","LU2097828631.EUR","LU2242644610.SGD","LU1831875114.USD","LU0502904849.HKD","LU0607220059.USD","LU0455707207.USD","BK1147","01911"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677901855","title":"Why Innovent Biologics (SEHK:1801) Is Back In The Spotlight","url":"https://stock-news.laohu8.com/highlight/detail?id=2677901855","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677901855?lang=en_us&edition=fundamental","pubTime":"2026-10-24 13:38","pubTimestamp":1792820291,"startTime":"0","endTime":"0","summary":"Innovent Biologics (SEHK:1801) just reported positive Phase 3 data for its Claudin 18.2 targeted antibody drug conjugate, arcotatug tavatecan, in advanced gastric and gastroesophageal junction cancer. The results support a priority-review new drug application in China.\nDespite the clinical win, Innovent Biologics' 30-day share price return is down 19.54% and the 7-day share price return is down 6.57%, while the 3-year total shareholder return of 84.89% points to a much stronger longer-term...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/why-innovent-biologics-sehk1801-is-back-in-the-spotlight","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/why-innovent-biologics-sehk1801-is-back-in-the-spotlight","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0455707207.USD","BK1583","LU0607220059.USD","LU2328871848.SGD","BK1161","LU0326950275.SGD","LU0149534421.HKD","DCF","LU2242644610.SGD","HK0000165453.HKD","LU2488822045.USD","LU1969619763.USD","LU2097828714.EUR","LU2097828631.EUR","LU0463099449.HKD","LU0502904849.HKD","LU2097828557.USD","LU0244354667.USD","LU1188198961.HKD","LU1831875114.USD","KURE","LU2097828474.EUR","LU2097828805.USD","BK1589","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677924368","title":"Innovent Biologics - Registrational Phase 3 G-Hope-001 Study Met Both Primary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2677924368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677924368?lang=en_us&edition=fundamental","pubTime":"2026-10-23 20:00","pubTimestamp":1792756801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nTUAP4RNG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0455707207.USD","LU1188198961.HKD","BK1161","BK1589","LU2328871848.SGD","LU1969619763.USD","LU2097828631.EUR","LU2242644610.SGD","LU0326950275.SGD","LU1831875114.USD","LU0244354667.USD","HK0000165453.HKD","LU2097828474.EUR","LU2097828557.USD","LU2488822045.USD","LU0607220059.USD","BK1583","KURE","01801","LU2097828805.USD","LU0463099449.HKD","LU0502904849.HKD","LU2097828714.EUR","LU0149534421.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677924359","title":"Innovent Biologics: Arcotatug Tavatecan Demonstrated Favorable Safety Profile, with a Low Incidence of Gastrointestinal Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2677924359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677924359?lang=en_us&edition=fundamental","pubTime":"2026-10-23 20:00","pubTimestamp":1792756801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nTUAP4RNG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2097828714.EUR","KURE","01801","LU0149534421.HKD","LU2097828557.USD","LU1969619763.USD","LU2488822045.USD","LU0607220059.USD","LU2097828805.USD","BK1161","BK1589","LU0455707207.USD","LU2097828474.EUR","LU2097828631.EUR","LU0502904849.HKD","LU1188198961.HKD","LU0244354667.USD","LU1831875114.USD","LU2328871848.SGD","LU0463099449.HKD","BK1583","LU2242644610.SGD","LU0326950275.SGD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188310052","title":"Schroders Limited Raises Stake in Innovent Bio by 926,500 Shares at HK$88.26 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1188310052","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188310052?lang=en_us&edition=fundamental","pubTime":"2026-10-23 19:28","pubTimestamp":1792754896,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, Schroders Limited increased its holdings in Innovent Bio (01801) by 926,500 shares on October 20, at a price of HK$88.2577 per share,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","LU0149534421.HKD","BK1589","EWH","BK1161","LU1188198961.HKD","LU2242644610.SGD","LU2097828474.EUR","LU2097828557.USD","LU0244354667.USD","BK1583","KURE","LU2097828714.EUR","LU0455707207.USD","LU1831875114.USD","LU2328871848.SGD","LU2488822045.USD","HK0000165453.HKD","LU0607220059.USD","LU1969619763.USD","LU0326950275.SGD","LU2097828631.EUR","LU0502904849.HKD","LU0463099449.HKD","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677929859","title":"Alert on Innovent Biologics Phase 3 Study Results Withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2677929859","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677929859?lang=en_us&edition=fundamental","pubTime":"2026-10-23 19:14","pubTimestamp":1792754097,"startTime":"0","endTime":"0","summary":"ADVISORY-Alert on Innovent Biologics Phase 3 study results withdrawnAn alert on Innovent Biologics1801.HKannouncing Phase 3 study results of arcotatug tavatecan in gastric cancer has been withdrawn af","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nTUA18F3RH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0244354667.USD","LU1188198961.HKD","LU1831875114.USD","LU0149534421.HKD","01801","LU0502904849.HKD","LU2097828474.EUR","LU0607220059.USD","LU2097828805.USD","LU2097828557.USD","LU2097828714.EUR","LU0326950275.SGD","LU0463099449.HKD","LU2488822045.USD","LU1969619763.USD","LU2097828631.EUR","BK1161","LU0455707207.USD","HK0000165453.HKD","LU2242644610.SGD","LU2328871848.SGD","BK1589","KURE","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677287949","title":"Innovent's Arcotatug Tavatecan Meets Survival Endpoints in Phase 3 Gastric Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2677287949","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677287949?lang=en_us&edition=fundamental","pubTime":"2026-10-23 18:10","pubTimestamp":1792750257,"startTime":"0","endTime":"0","summary":"Innovent's Arcotatug Tavatecan Meets Survival Endpoints in Phase 3 Gastric Cancer TrialInnovent Biologics announced Oct. 23, 2026, that arcotatug tavatecan met both primary survival endpoints in the P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nNDLWnktX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU0502904849.HKD","01801","LU0149534421.HKD","BK1589","01911","BK1147","LU2097828805.USD","LU1831875114.USD","BK1583","LU2097828474.EUR","LU2328871848.SGD","BK1161","HK0000165453.HKD","LU2097828631.EUR","LU2488822045.USD","LU0463099449.HKD","LU0455707207.USD","LU2097828557.USD","LU0607220059.USD","LU2242644610.SGD","KURE","LU1188198961.HKD","LU0326950275.SGD","LU2097828714.EUR","LU0244354667.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677928204","title":"2026 Esmo Lba | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (Cldn18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of Pfs and Os","url":"https://stock-news.laohu8.com/highlight/detail?id=2677928204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677928204?lang=en_us&edition=fundamental","pubTime":"2026-10-23 18:10","pubTimestamp":1792750201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nTUA18F3RH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0502904849.HKD","LU2097828557.USD","LU0607220059.USD","LU1969619763.USD","LU2097828805.USD","LU2097828474.EUR","LU0244354667.USD","01801","LU2242644610.SGD","LU2488822045.USD","LU0455707207.USD","KURE","LU2097828631.EUR","LU0149534421.HKD","LU1831875114.USD","HK0000165453.HKD","BK1161","BK1589","LU2328871848.SGD","BK1583","LU2097828714.EUR","LU1188198961.HKD","LU0326950275.SGD","LU0463099449.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677940786","title":"1 Boom in China, India, Brazil Could Create $22 Bln Market by 2035, J.P. Morgan Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2677940786","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677940786?lang=en_us&edition=fundamental","pubTime":"2026-10-23 17:55","pubTimestamp":1792749318,"startTime":"0","endTime":"0","summary":"GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan saysOct 23 (Reuters)-The combined China-India-Brazil market for weight-loss drugs could grow to $22 billion by 2035 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nL4N4690FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","HK0000165453.HKD","LU2097828805.USD","KURE","LU0326950275.SGD","LU2097828631.EUR","01801","LU0463099449.HKD","LU2097828474.EUR","LU2097828714.EUR","BK1589","BK1161","LU0607220059.USD","LU2097828557.USD","LU2488822045.USD","BK1583","LU0149534421.HKD","LU2242644610.SGD","LU1969619763.USD","LU2328871848.SGD","LU0244354667.USD","LU0502904849.HKD","LU1188198961.HKD","LU1831875114.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178934247","title":"Morgan Stanley: Preview of Q4 Catalysts for Chinese Biotech Stocks, Sector Rated \"Attractive\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1178934247","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178934247?lang=en_us&edition=fundamental","pubTime":"2026-10-23 15:18","pubTimestamp":1792739896,"startTime":"0","endTime":"0","summary":"Morgan Stanley has released a research report identifying and previewing potential catalysts that could affect the stock prices of Chinese biotech companies in the fourth quarter of 2026, assigning...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0098860793.USD","LU2097828474.EUR","BK1589","LU2476274308.USD","KBWB","LU0106831901.USD","BK4585","LU2242644610.SGD","BK4588","LU2328871848.SGD","LU0158827781.USD","02162","BK1587","LU0053666078.USD","LU0320765646.SGD","LU0234570918.USD","BK1161","LU2264538146.SGD","BK1574","LU0971096721.USD","LU2487616109.SGD","LU0463099449.HKD","LU2133065610.SGD","LU2089284900.SGD","LU2089283258.USD","BK4534","LU2097828714.EUR","LU0502904849.HKD","LU1720051108.HKD","LU1188198961.HKD","LU1732800096.USD","TBXU","LU1969619763.USD","LU0912757837.SGD","LU2347655156.SGD","LU1831875114.USD","LU0455707207.USD","LU1791710400.SGD","LU1363072403.SGD","LU0882574139.USD","LU0149534421.HKD","LU1732799900.SGD","LU2028103732.USD","LU0006306889.USD","BK4504","09969","LU1668664300.SGD","IE00B775SV38.USD","LU1791710582.SGD","LU0225283273.USD","LU1074936037.SGD","BK4516","LU0557290698.USD","LU2271345857.HKD","LU0158827948.USD","LU0244354667.USD","LU0314104364.USD","BK1583","IE00BZ1G4Q59.USD","IE00B5MMRT66.SGD","LU0795875169.SGD","IE00BPRC5H50.USD","LU1720051017.SGD","LU2357305700.SGD","LU1988902786.USD","LU1162221912.USD","LU0106261372.USD","LU2023251221.USD","IE00BKVL7J92.USD","IE00B3S45H60.SGD","LU2097828805.USD","LU1244550577.SGD","LU1989772840.SGD","01801","LU2097828557.USD","LU1244550494.USD","IAI","MS","LU2778985437.USD","IE00B543WZ88.USD","LU2476274720.SGD","KURE","BIOY","LU0267386448.USD","BK4581","LU1244550221.USD","LU0210528500.USD","LU1548497426.USD","02256","LU0607220059.USD","LU1989772923.USD","LU2097828631.EUR","LU0528227936.USD","LU2111349929.HKD","LU1064131342.USD","LU2488822045.USD","LU0390134368.USD","BK4127","LU0795875086.SGD","LU0326950275.SGD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169496607","title":"Movement Alert｜INNOVENT BIO Intraday Rise 3.06% in Regular Trading, IBI3003 data and a higher target price supported sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=1169496607","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169496607?lang=en_us&edition=fundamental","pubTime":"2026-10-23 14:15","pubTimestamp":1792736122,"startTime":"0","endTime":"0","summary":"On October 23, INNOVENT BIO rose 3.06% intraday in Regular Trading, trading at HK$84.15, with turnover of HK$1.103 billion.The move coincided with continued market digestion of the company’s recently...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Innovent Bio up on IBI3003 data and Buy target raise","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0767},{"period":"1month","weight":-0.1906},{"period":"3month","weight":-0.1003},{"period":"6month","weight":-0.1033},{"period":"1year","weight":-0.0627},{"period":"ytd","weight":0.0584}],"compareEarnings":[{"period":"1week","weight":-0.0346},{"period":"1month","weight":-0.0599},{"period":"3month","weight":-0.1072},{"period":"6month","weight":-0.1061},{"period":"1year","weight":-0.1283},{"period":"ytd","weight":-0.101}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.043223},{"month":5,"riseRate":0.375,"avgChangeRate":0.014737},{"month":6,"riseRate":0.625,"avgChangeRate":0.116146},{"month":7,"riseRate":0.5,"avgChangeRate":0.019948},{"month":8,"riseRate":0.75,"avgChangeRate":0.024842},{"month":9,"riseRate":0.5,"avgChangeRate":0.021235},{"month":10,"riseRate":0.25,"avgChangeRate":-0.042121},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"INNOVENT BIO","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOVENT BIO,01801,INNOVENT BIO股票,INNOVENT BIO股票老虎,INNOVENT BIO股票老虎国际,INNOVENT BIO行情,INNOVENT BIO股票行情,INNOVENT BIO股价,INNOVENT BIO股市,INNOVENT BIO股票价格,INNOVENT BIO股票交易,INNOVENT BIO股票购买,INNOVENT BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}